N-[5-({3-[5-(Acetyl-hydroxy-amino)-pentylcarbamoyl]-propionyl}-hydroxy-amino)-pentyl]-N'-{5-[2-(3,5-dimethyl-adamantan-1-yl)-acetylamino]-pentyl}-N'-hydroxy-succinamide

ID: ALA4210466

Chembl Id: CHEMBL4210466

PubChem CID: 145963844

Max Phase: Preclinical

Molecular Formula: C39H68N6O9

Molecular Weight: 765.01

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CC12CC3CC(C)(CC(C)(C3)C1)C2

Standard InChI:  InChI=1S/C39H68N6O9/c1-30(46)43(52)20-10-4-7-17-40-32(47)13-15-35(50)44(53)21-11-5-8-18-41-33(48)14-16-36(51)45(54)22-12-6-9-19-42-34(49)26-39-25-31-23-37(2,28-39)27-38(3,24-31)29-39/h31,52-54H,4-29H2,1-3H3,(H,40,47)(H,41,48)(H,42,49)

Standard InChI Key:  QIWTWOZMQZRBET-UHFFFAOYSA-N

Alternative Forms

  1. Parent:

    ALA4210466

    ---

Associated Targets(Human)

SK-N-BE(2)-M17 (195 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Astrocyte (46 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 765.01Molecular Weight (Monoisotopic): 764.5048AlogP: 4.47#Rotatable Bonds: 26
Polar Surface Area: 208.92Molecular Species: NEUTRALHBA: 9HBD: 6
#RO5 Violations: 2HBA (Lipinski): 15HBD (Lipinski): 6#RO5 Violations (Lipinski): 3
CX Acidic pKa: 7.92CX Basic pKa: CX LogP: 0.93CX LogD: 0.81
Aromatic Rings: Heavy Atoms: 54QED Weighted: 0.04Np Likeness Score: 0.01

References

1. Telfer TJ, Liddell JR, Duncan C, White AR, Codd R..  (2017)  Adamantyl- and other polycyclic cage-based conjugates of desferrioxamine B (DFOB) for treating iron-mediated toxicity in cell models of Parkinson's disease.,  27  (8): [PMID:28285915] [10.1016/j.bmcl.2017.03.001]

Source